Benralizumab in the Treatment of Patients With Severe Asthma With ABPA

SELECT INCLUSION CRITERIA * Female and Male patients aged 18-75 years inclusively at the time of Visit 1 with a physician diagnosis of Allergic Bronchopulmonary Aspergillosis has met the ISHAM Working Group Diagnostic Criteria for ABPA: * Predisposing condition: Bronchial asthma * Obligatory criteria (both should be present) * Type I aspergillus skin test positive (immediate cutaneous hypersensitivity Aspergillus antigen) or elevated IgE level against Aspergillus fumigatus (Af) * Aspergillus niger or Aspergillus flavus may be eligible provided antigen-specific IgE and IgG measurements are available for use. * Elevated total IgE levels (\>1,000IU/mL)\* * Other criteria (at least two of three) * Presence of precipitating or IgG antibodies against Af in serum * Radiographic pulmonary opacities consistent with ABPA * Total eosinophil count \>500 cells/uL in steroid naïve patients (may be historical) * (if the patient meets all other criteria, an IgE value \<1,000 IU/mL may be acceptable) * Severe chronic asthma (for at least 12 months) requiring treatment with high dose ICS plus asthma controller prior to Visit 1 * Other acceptable asthma controllers include long acting bronchodilators (e.g. a long acting beta-agonist (LABA) or long-acting muscarinic antagonists (LAMA)), a leukotriene inhibitor, theophylline preparations and/or maintenance OCS (daily or every other day OCS requirement in order to maintain asthma control * Documented current treatment with high daily doses of ICS ( \>500ug of FP equivalent) plus at least one other asthma controller for at least 3 months prior to Visit 1 * For ICS/LABA combination preparation, highest-strength maintenance doses approved in the U.S. will meet this criterion * If the ICS and the other asthma controller therapies are given by separate inhalers, then the patient must be on a high daily ICS dose for 3 months prior to entering the study. * History of at least 2 asthma exacerbations while on ICS plus another asthma controller (see inclusion criterion 2 for examples) that required treatment with systemic corticosteroids (IM, IV, or oral) in the 12 months prior to Visit 1. For patients receiving oral corticosteroids as a maintenance therapy, an exacerbation is defined as a temporary increase of their maintenance dose for a minimum of 3 days. * Weight \> 40kg SELECT EXCLUSION CRITERIA * Clinical important pulmonary disease other than asthma with allergic bronchopulmonary aspergillosis (ie. chronic obstructive pulmonary disease (COPD), cystic fibrosis, sarcoid, and pulmonary fibrosis) * History of anaphylaxis to any biologic therapy * Known history of allergy or hypersensitivity reaction to benralizumab or any of its components * Current smokers or former smokers with a smoking history of \> 10 pack years. A former smoker is defined as a patient who quit smoking at least 6 months prior to Visit 1. * Currently pregnant, breastfeeding, or lactating women * Concurrent enrollment in another interventional or post-authorization safety study, unless it is observational.